概括
再次暴露于哈洛麻醉可能会增加肝酶,特别是在以前少于四次暴露于哈洛的患者中. 这项研究调查了甲.
科学领域:
- 麻醉学 麻醉学
- 肝病学 肝病学是一种肝病学.
- 临床生物化学 临床生物化学
背景情况:
- 哈洛是一种广泛使用的挥发性麻醉剂.
- 以前接触过哈洛可能会增加肝脏不良反应的风险.
- 在接受重复麻醉的患者中,监测肝功能至关重要.
研究的目的:
- 为了研究重复的哈洛麻醉对肝功能的影响.
- 为了确定之前的甲暴露是否会影响肝损伤的风险.
- 为了比较服用哈洛和对照麻醉剂的患者之间的肝酶水平.
主要方法:
- 随机对照试验,每组有76名患者.
- 患者接受了氨酸或对照麻醉剂 (无氨酸装置).
- 血清氨酸-氧酸转胺酶 (S.G.O.T.) 是一种 在手术前和手术后2-3周的连续测量了血水平.
主要成果:
- 显著更高的S.G.O.T.显著更高的S.G.O.T. 与对照组相比,在哈洛组观察到高含量.
- 提升的S.G.O.T. 提升的S.G.O.T. 这些水平主要在患者中观察到,他们以前服用的哈洛麻醉剂少于四次.
- 哈洛组的一名患者发生肝细胞亡;另外两名患者S.G.O.T.升高. 在再次暴露时.
结论:
- 再次暴露于哈洛麻醉可以导致肝酶升高.
- 患者之前的甲暴露有限,似乎更容易受到这些影响.
- 需要进一步调查氨酸诱导的肝损伤.
相关概念视频
Hepatic Drug Excretion: Influencing Factors
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...


